chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Symptoms of Covid (fatigue, cough, congestion, hiccups). On Sat (05Feb2022) I tested +./ I still tested +[health] for covid on Wed 09Feb2022.; Symptoms of Covid (fatigue, cough, congestion, hiccups). On Sat (05Feb2022) I tested +./ I still tested +[health] for covid on Wed 09Feb2022.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 71 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 01Oct2021 14:00 (Lot number: FC3184) at the age of 71 years as dose 3 (booster), single, intramuscular, administered in arm right, administration date 06Mar2021 14:00 (Lot number: EN6205) as dose 2, single and intramuscular, administered in arm right, administration date 13Feb2021 10:00 (Lot number: EM9809) as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: COVID-19 (medically significant) with onset 05Feb2022, outcome "not recovered", VACCINATION FAILURE (medically significant) with onset 05Feb2022, outcome "unknown" and all described as "Symptoms of Covid (fatigue, cough, congestion, hiccups). On Sat (05Feb2022) I tested +./ I still tested +[health] for covid on Wed 09Feb2022.". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (09Feb2022) positive; (05Feb2022) positive. On Fri 04Feb2022 he had symptoms of covid [Fatigue, Cough, congestion, Hiccups]. On sat 05Feb2022 he tested positive using OTC test [Binax Now]. On Saturday and Sunday the symptoms were at their worst, but he never had shortness of breath or a fever. By Tuesday he was almost fully recovered. It was reported that with vaccine #2 and Booster (#3), he developed Hiccups that lasted over 2hrs at a time and gone the next day. With his current covid infection- Hiccups were started on Friday, by Saturday &Sunday (05Feb2022& 06Feb2022) that lasted 5 to 6 hours, but they tapered out on Mon (07Feb2022) and never gone by Tuesday.
Experienced COVID; Experienced COVID; This is a solicited report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4419843-00 (Company).  A 14-year-old female patient received BNT162b2 (BNT162B2), on 22Aug2021 as dose 1, single (Batch/Lot number: unknown), on 02Sep2021 as dose 2, single (Batch/Lot number: unknown) and on 30Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 14 years, all intramuscular for covid-19 immunisation; adalimumab (HUMIRA), (Batch/Lot number: unknown) at unk (citrate free), subcutaneous for uveitis, polyarthritis, juvenile idiopathic arthritis. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant) all with onset May2022, outcome "recovered" (2022) and all described as "Experienced COVID". The action taken for adalimumab was unknown.  Clinical information: Solicited report by a consumer with an event of non-serious COVID with Humira (Adalimumab). In May2022, the patient experience COVID. In 2022 the COVID resolved. Pfizer BioNTech COVID-19 Vaccine (Tozinameran) was also considered suspect. It was Unknown if patient was enrolled in a COVID-19 Vaccine Trial. Primary reporter did not have the lot number information, because the packaging was discarded. Did Event Abate After Stopping Drug?: NA. The reporter's causality for the event(s) of COVID for Humira was not provided.  The reporter considered "experienced covid" related to BNT162b2.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: As there is limited information in the case provided, the causal association between the events drug ineffective and suspected covid 19 with the suspect product BNT162b2 cannot be excluded. The case will be reassessed once new information is available.
COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non-HCP). The reporter is the patient.  A 66-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 08Mar2021 as dose 1, single (Lot number: EN6205), in right arm, on 26Mar2021 as dose 2, single (Lot number: ER8727), in right arm, on 05Oct2021 as dose 3 (booster), single (Lot number: FF8839), in right arm and on 15Apr2022 as dose 4 (booster), single (Lot number: FK9893), in right arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 27Jul2022, outcome "unknown" and all described as "COVID-19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (23Jul2022) Negative; (27Jul2022) Positive; (29Jul2022) Negative; (30Jul2022) Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19 which included Paxlovid, start on 19Jul2022 and stop on 24Jul2022.  Clinical information: The patient had received vaccine and also had administered another medication (which are captured in linked case 202201022902) within 2 weeks of vaccine administration.  No follow-up attempts are possible. No further information is expected.
Was not good at all; Fell asleep for 3 hours; Chills/was freezing; Severe fever/had a temperature; Arm hurt/My arm is still tender/legs hurt so bad; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Arm hurt/My arm is still tender/legs hurt so bad), FEELING ABNORMAL (Was not good at all), SOMNOLENCE (Fell asleep for 3 hours), CHILLS (Chills/was freezing) and PYREXIA (Severe fever/had a temperature) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 022C21A, 025B21A and 010A21A) for COVID-19 vaccination.     Concurrent medical conditions included Dermatomyositis and Immunocompromised. Concomitant products included MYCOPHENOLATE MOFETIL (CELLCEPT [MYCOPHENOLATE MOFETIL]) for Dermatomyositis.   On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Sep-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Sep-2021, the patient experienced PAIN IN EXTREMITY (Arm hurt/My arm is still tender/legs hurt so bad). On 02-Sep-2021, the patient experienced FEELING ABNORMAL (Was not good at all), SOMNOLENCE (Fell asleep for 3 hours), CHILLS (Chills/was freezing) and PYREXIA (Severe fever/had a temperature). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. On 02-Sep-2021, FEELING ABNORMAL (Was not good at all), SOMNOLENCE (Fell asleep for 3 hours), CHILLS (Chills/was freezing) and PYREXIA (Severe fever/had a temperature) had resolved. At the time of the report, PAIN IN EXTREMITY (Arm hurt/My arm is still tender/legs hurt so bad) outcome was unknown.            This case was linked to MOD-2021-310491, MOD-2021-310465 (Patient Link).
Patient not going to take 2nd shot; Chronic,daily migraine headaches; Headache; This spontaneous case was reported by a consumer and describes the occurrence of OFF LABEL USE (Patient not going to take 2nd shot), MIGRAINE (Chronic,daily migraine headaches) and HEADACHE (Headache) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced OFF LABEL USE (Patient not going to take 2nd shot), MIGRAINE (Chronic,daily migraine headaches) and HEADACHE (Headache). At the time of the report, OFF LABEL USE (Patient not going to take 2nd shot), MIGRAINE (Chronic,daily migraine headaches) and HEADACHE (Headache) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Description:  1st communication was on 2021-05-03 20:05 2nd communication was on 2021-05-03 19:56 3rd communication was on 2021-05-04 07:54 4th communication was on 2021-05-04 10:00 5th communication was on 2021-05-04 09:33 Patient clearly stated that he is not going to take the second shot. For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments. Concomitant product was not provided. treatment was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 09-May-2021: NNI On 21-May-2021: NNI
12/1-Nausea/Vomiting, Fever, Arm Pain; 12/2-Delirium--was transported to hospital-low potassium, 2 small blood clots in lung (PE)-patient started on Eliquis
Pt had trouble breathing. I asked pt if she could breathe and she said no. So I administered an EPIPEN and her breathing was relieved. Pt called son, did not want to go to hospital. Pt's doctors said it was an asthma attack.
After receiving PREVNAR 13 intramuscularlly in the left arm on 07/16/2016 pt experienced redness on torso, right arm, and right leg in the days following the immunization. The husband reported on 08/30/2016 pt has experienced difficulty in walking since 07/16/2016. Pt was seen locally by Dr. Pt was referred to Neurologist. (08/31/2016) Husband states Dr. indicated the immunization was the source of the patient's difficulty. Dr. opinion was the patient is in the process of recovery, which may take some time.
Arm swollen (near injection site); Slight fever; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE SWELLING (Arm swollen (near injection site)), PYREXIA (Slight fever) and FATIGUE (Fatigue) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 038C21A and 025A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 06-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE SWELLING (Arm swollen (near injection site)), PYREXIA (Slight fever) and FATIGUE (Fatigue). At the time of the report, VACCINATION SITE SWELLING (Arm swollen (near injection site)), PYREXIA (Slight fever) and FATIGUE (Fatigue) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Heart rate: 85-124 (abnormal) abnormal.         No concomitant medications were provided. No treatment medication were provided. Heart rate is between 85-124 beats per min, how much patient rest.   This case was linked to MOD-2021-368796, MOD-2021-368799 (Patient Link).
Hospitalized 1/2/2022; COVID-19 positive 1/2/2022; fully vaccinated Admission Date: 1/2/2022 Admitting Diagnoses: AKI Discharge Date: 1/6/2022 Details of Hospital Stay PRESENTING PROBLEM: Acute on chronic kidney failure    HOSPITAL COURSE: Patient is a 68 year old male with PMH of type 2 diabetes, hyperlipidemia, HFpEF, essential hypertension, and obesity. He presented with cough, generalized weakness, fatigue, and poor appetite. He was found to have COVID pneumonia and is fully vaccinated. Patient never became hypoxic and was not started on steroids. He was found to have an AKI on CKD3 likely due to his poor oral intake. He has been started on IVF and his kidney function slowly returned to baseline. The patient also started to feel better overall and his PO intake started to increase. His kidney function was close to baseline at time of discharge. His lasix was restarted day of discharge as the patient was slightly fluid positive. His lisinopril was held at discharge and the patient should follow up with his PCP early next week for repeat blood work to determine the appropriateness of restarting medication. The patient was up titrated on hydralazine to help control his blood pressure in its absence. The patient should weigh himself daily and call his PCP sooner if his weight increases more then 5lbs.  In regards to COVID-19 the patient remained asymptomatic and CXR was clear from infiltrates. As patient symptoms were more then 2 weeks ago he no longer needs to quarantine. Patient did have some low blood sugars while inpatient thought to be secondary to over medication of insulin. The patient was instructed to closely monitor his blood sugar at home and make adjustments if necessary. The patient was hemodynamically stable at time of discharge
At about 10pm the injection site pain had radiated to my armpit and breast area. I took ibuprofen and tried to go to sleep. I was unable to sleep on my left side as normal. Around 12:30am I woke up cold, shivering violently, with a fever of 103.°3. My feet were also burning.  I woke up around 2:30am. Fever was down to about 102.4°, feet were still burning and my face and eyes were swollen. I took more ibuprofen and put used cold compress on my eyes. Around 4:30am I woke up with abdominal pain and pain in my hips. Fever was lower, eyes were better but face still swollen and feet still burning. I called off work at that time. By about 8am fever broke and have just had an intense headache.
I was informed by a friend of the patient that the patient has been experiencing pain and swelling in the immunized arm. I have not seen the patient since immunizing her against influenza on 9-25-12. Patient was referred to see a physician if she continues to experience discomfort.
PATIENT PRESENTED TO PHARMACY REQUESTING J & J COVID-19 VACCINE. WHEN ASKED IF HE HAD PREVIOUSLY RECEIVED A COVID-19 VACCINE HE RESPONDED NO AND ALSO CHECKED NO ON VACCINE CONSENT FORM. UPON DOCUMENTING DOSE IN CVMS IT WAS DISCOVERED HE HAD FINISHED THE PFIZER SERIES OF THE COVID-19 VACCINE ON 4/13. NO ADVERSE EVENTS WERE REPORTED AFTER ADMINISTRATION OF THE VACCINE.
Burning sensation; Itchy sensation; The area of injection was hot; The area of injection was red; A spontaneous report was received from a consumer, concerning herself, a 68-year-old, female patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced burning sensation, itchy sensation, the area of injection site was hot and red.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 02-JAN-2021, the patient received their first of two planned doses of mRNA-1273 (Lot number: 039K20A) intramuscularly for prophylaxis of COVID-19 infection.   On 09-JAN-2021, after the first dose of vaccine she started having a burning and Itchy sensation. When she rolled up her sleeves the area of injection was noticed to be red and hot. Patient was treated with paracetamol 1000mg and diphenhydramine 25 mg, but it was not working, and she was still having the same symptoms.  Action taken with mRNA-1273 in response to the events were not reported.   The outcome of events, burning sensation, itchy sensation, the area of inject site was hot and red were considered not resolved at the time of this report.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Pt laid down for imminization, five minutes into sitting down, she said she felt funny and passed out, resopnded immediately to her name. She was slightly cold a clammy.
Chest inflammation  Shortness of breath Coughing  Headache  Low grade fever Muscle  aches & pain  Joint pain Lethargic  Flu like symptoms  Sore arm Congestion  Sinuses
shingle like hives; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (shingle like hives) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced URTICARIA (shingle like hives). At the time of the report, URTICARIA (shingle like hives) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Reporter did not allow further contact
Caller has had 3 shots total (2 primary and 1 booster) of Pfizer; Caller has had 3 shots total (2 primary and 1 booster) of Pfizer; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Caller has had 3 shots total (2 primary and 1 booster) of Pfizer". Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Patient started taking Paxlovid two days ago and she sick. Really sick. Caller has had 3 shots total (2 primary and 1 booster) of Pfizer and was asking how soon can she get another booster. Last booster was received over a year ago.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Patient in office 11/03/2022 to receive these vaccinations. I noticed on the record these were given before the minimum validation date on 09/17/2022. Last dose prior to that was 08/31/2022.
severe chest pains/last about 20 minutes and then go away; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (severe chest pains/last about 20 minutes and then go away) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced CHEST PAIN (severe chest pains/last about 20 minutes and then go away). At the time of the report, CHEST PAIN (severe chest pains/last about 20 minutes and then go away) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication details was reported. No treatment medication details was reported.   Reporter did not allow further contact
Received dose 1 of vaccine and on day of and day after of vaccine administration experienced headache, chills, fatigue. and body aches--all flu like symptoms  pregnancy info not avl from report filed.
fever blisters on mouth 25AUG98-26AUG98 noticed blisters on hands w/in 2 days blisters on both days; blah,tired, cold, coughing;sent home for work secondary inc blisters;dx as adverse rxn to MMR;
developed fever and chills within 24 hours of vaccine and at 4 weeks out had unprovoked acute DVT in the axillary and subclavian vein on the side of the vaccine.
Redness and itching at the injection site. Treated with Benadryl, at 09:15.
Injection site is red and swollen. Inflamed area extends to the opposite side of her arm. Area is somewhat painful. It also itches. Tx: TYLENOL and Hydrocortisone cream.
Tactile temp noted, mom called next AM- screamed & irritable from time got home until that morning; then no problems;
Little bit of red/ another red blotchy area in the muscle where vaccination was adminstered; Little bit of itchiness; kind of like a rash; little red bump; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Little bit of red/ another red blotchy area in the muscle where vaccination was adminstered), PRURITUS (Little bit of itchiness), RASH (kind of like a rash) and VACCINATION SITE SWELLING (little red bump) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 018B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 31-Mar-2021, the patient experienced PRURITUS (Little bit of itchiness), RASH (kind of like a rash) and VACCINATION SITE SWELLING (little red bump). On 01-Apr-2021, the patient experienced ERYTHEMA (Little bit of red/ another red blotchy area in the muscle where vaccination was adminstered). At the time of the report, ERYTHEMA (Little bit of red/ another red blotchy area in the muscle where vaccination was adminstered), PRURITUS (Little bit of itchiness), RASH (kind of like a rash) and VACCINATION SITE SWELLING (little red bump) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications were not provided by the reporter.  Patient was treated with antihistamines.   Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2021: Added vaccine second dose and its event details, treatment information and updated outcome of the events.